To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment (Navigator)

A Randomized, Double-Blind, Placebo-controlled, Parallel Arm, 52-week Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of Two Doses of EXPD-101 in Participants With COPD

This is a Phase 2 study of the efficacy, safety, tolerability and pharmacokinetics of two doses of EXPD-101 in participants with COPD. Study participants will be randomized to receive either study drug or placebo administered once daily for 52 weeks.

Study Overview

• Status: Recruiting
• Conditions: Chronic Obstructive Pulmonary Disease (COPD)
• Intervention / Treatment: Drug: EXPD-101/FXS7553 Dose 1; Drug: EXPD-101/FXS7553 Dose 2; Drug: Placebo

• Study Type: Interventional
• Enrollment (Estimated): 600
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Geoffrey Gilmartin, MD; Phone Number: 617-775-9882; Email: geoff.gilmartin@expeditiontx.com

Study Locations

• United States
  • Arizona
    • Phoenix, Arizona, United States, 85012
      • Recruiting
      • DM Clinical Research - Phoenix
      • Principal Investigator: Danielle Armas
      • Contact: Jade Perez; Phone Number: 6232320800; Email: jade.perez@dmclinical.com
  • California
    • Northridge, California, United States, 91324
      • Recruiting
      • California Medical Research Associates Inc.
      • Principal Investigator: Jigar Kadakia
      • Contact: Chrismarie Goonarathne; Phone Number: 8183491979; Email: chrismarie.cmra@gmail.com
  • Colorado
    • Aurora, Colorado, United States, 80012
      • Recruiting
      • Lynn Institute of Denver
      • Principal Investigator: Timothy Colander
      • Contact: Jacqueline Moore; Phone Number: 7207083192; Email: jmoore@lhsi.net
  • Florida
    • Leesburg, Florida, United States, 34748
      • Recruiting
      • Clinical Site Partners, LLC Leesburg dba Flourish Research
      • Contact: Jose Diaz; Phone Number: 3524357240; Email: jdiazmd@flourishresearch.com
    • Miami, Florida, United States, 33135
      • Recruiting
      • Suncoast Research Group, LLC Miami - Little Havana dba Flourish Research
      • Principal Investigator: Mark Kutner
      • Contact: Jaymie Marquez; Phone Number: 3052557452; Email: jmarquez@flourishresearch.com
    • Orange, Florida, United States, 32763
      • Recruiting
      • Optimal Research Sites
      • Contact: Janyssa Balmes; Phone Number: 3862185911; Email: jbalmes@optimalresearchsites.net
      • Principal Investigator: Kristyna Paradis
  • Georgia
    • Rincon, Georgia, United States, 31326
      • Not yet recruiting
      • Centricity Research Columbus
      • Principal Investigator: Maria Mascolo
      • Contact: Ashley King; Phone Number: 8437255067308; Email: aking@clinicaltrialssc.com
  • Indiana
    • Indianapolis, Indiana, United States, 46254
      • Recruiting
      • DM Clinical Research-Indianapolis
      • Principal Investigator: Brandon Essink
      • Contact: Stephanie Samayoa; Phone Number: 4632713179; Email: stephanie.samayoa@dmclinical.com
  • Kansas
    • Topeka, Kansas, United States, 66606
      • Recruiting
      • Cotton O'Neil Clinical Research Center
      • Contact: Ambrosee Wilkinson; Phone Number: 7853680741; Email: ambrosee.wilkinson@stormontvail.org
      • Principal Investigator: Najm Salah
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States, 19107
      • Recruiting
      • DM Clinical Research - Philadelphia
      • Contact: Michael Coyle; Phone Number: 4453009011; Email: michael.coyle@dmclinical.com
      • Principal Investigator: David Wheeler
  • Texas
    • Tomball, Texas, United States, 77375
      • Recruiting
      • DM Clinical Research- Tomball
      • Principal Investigator: Mustafa Naeem
      • Contact: Maryam Jamil; Phone Number: 2815170550; Email: maryam.jamil@dmclinical.com
  • Virginia
    • Burke, Virginia, United States, 22015
      • Recruiting
      • Burke Internal Medicine, Inc.
      • Principal Investigator: Nashwa Gabra
      • Contact: Amy Aziz; Phone Number: 7034559711; Email: amy@burkeclinicaltrials.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Provided written informed consent for the study
2. Body mass index (BMI) ≥ 18.5 kg/m2 and < 35 kg/m2 at screening (weight ≥ 50 kg for males and ≥ 45 kg for females)
3. Diagnosis of COPD for at least 1 year
4. COPD with physician-confirmed diagnosis of chronic bronchitis (persistent, productive cough and sputum for at least 3 months in the past year)
5. At least 2 moderate or > 1 severe exacerbation within 12 months prior to screening
6. Current or ex-tobacco smokers with history of ≥ 10 pack-years (1 pack year = 20 cigarettes smoked per day for 1 year);

7. Stable maintenance therapy with either dual or triple inhaled therapy for ≥ 3 months prior to enrollment per below:

   1. Dual therapy: long-acting beta-2 agonist/muscarinic antagonist (LABA/LAMA) or inhaled corticosteroids (ICS)/LAMA, or ICS/LABA OR
   2. Triple therapy: ICS/LAMA/LABA
8. Post-BD FEV1/FVC < 0.7 and post-BD FEV1(% predicted) ≥ 40% at Screening
9. COPD Assessment Test (CAT) score ≥ 10 at Screening
10. If participant is of childbearing potential, must commit to practicing highly effective methods of birth control and not donating eggs during the study and at least 14 days after the last dose.

11. Male participants commit to the following during the study and for at least 14 days after the last dose:

    1. Practice true sexual abstinence (refrain from heterosexual intercourse)
    2. Use a condom with any female partner of childbearing potential and ensure that the partner uses a highly effective contraceptive method (eg, IUD/IUS, combined hormonal contraception, progestogen-only contraception, or bilateral tubal occlusion).
    3. Be vasectomized (≥ 3 months prior to screening)
    4. Refrain from donating sperm during the Treatment Period and for at least 14 days after the last dose of the IP

Exclusion Criteria:

1. COPD exacerbation within the 4 weeks prior to randomization.
2. Clinically important pulmonary disease other than COPD (eg, asthma, active lung infection, clinically significant bronchiectasis, pulmonary fibrosis, cystic fibrosis, lung cancer, alpha-1 antitrypsin deficiency, tuberculosis).
3. Significant immunodeficiency and/or positive serological tests for hepatitis B, hepatitis C, or known human immunodeficiency virus (HIV) infection.
4. Pneumonia requiring antibiotics or antiviral medication within 28 days prior to Visit 1.
5. History of clinically significant infection (excluding pneumonia), acute upper or lower respiratory infection, requiring antibiotics or antiviral medication within 14 days prior to Visit 1.
6. Evidence of active liver disease (with or without ongoing treatment)
7. Participants with a QT interval, from the ECG conducted at Screening Visit 1, corrected with Fridericia's formula (QTcF) > 450 msec (or QTcF > 480 msec in participants with bundle branch block).
8. Current or history, within the past year of Visit 1, of substance and/or alcohol abuse.

9. History of cancer except:

   1. Participants who have had basal cell carcinoma, localized squamous cell carcinoma of the skin or in situ carcinoma of the cervix are eligible to participate in the study provided that curative therapy was completed at least 12 months prior to Visit 1
   2. Participants who have had other malignancies are eligible provided that curative therapy was completed at least 5 years prior to Visit 1
10. Any clinically significant abnormal findings in physical examination, vital signs, hematology, clinical chemistry, or urinalysis during Screening Period, which in the opinion of the investigator, may put the participant at risk because of his/her participation in the study, or may influence the results of the study, or the participant's ability to complete the entire duration of the study.
11. Known history of allergy or reaction to any component of the investigational product formulation
12. Current treatment with biologic drugs for COPD (eg, dupilumab, mepolizumab) or use of Therapeutics, biologics within 5 half-lives or 4 months, whichever is longer, from randomization
13. Current long-term treatment with oxygen therapy > 12 hours per day
14. Use of immunoglobulin or blood products in 30 days prior to Screening
15. Received a live attenuated vaccine within 30 days prior to Screening
16. Participants who are participating in the acute phase of a pulmonary rehabilitation program, i.e. who started rehabilitation < 4 weeks prior to screening (Note: participants in the maintenance phase of a rehabilitation program can be included).
17. History or active conditions associated with the onset of non-hereditary palmoplantar keratosis:
18. Have any tooth that can potentially cause pain or infection as noted in the oral exam unless they are corrected before the study

19. Has active periodontal disease and are either:

    1. Currently treated by a dentist for this condition or
    2. Expected to have periodontal disease-related procedures within the study period
20. Are scheduled to have tooth extraction that will occur during the study period

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: EXPD-101/FXS7553 Dose 1; Participants will receive EXPD-101/FXS7553 Dose 1, orally, once daily, for 52 weeks.	Drug: EXPD-101/FXS7553 Dose 1; Oral tablet
Experimental: EXPD-101/FXS7553 Dose 2; Participants will receive EXPD-101/FXS7553 Dose 2, orally, once daily, for 52 weeks.	Drug: EXPD-101/FXS7553 Dose 2; Oral tablet
Placebo Comparator: Placebo; Participants will receive a EXPD-101/FXS7553-matching placebo, tablets orally, once daily, for 52 weeks.	Drug: Placebo; EXPD-101/FXS7553 - matching oral tablet.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Annualized rate of moderate and severe COPD exacerbations	Effect of EXPD-101/FXS7553 compared with placebo on rate of moderate and severe COPD exacerbations. Moderate COPD exacerbation is defined as acute exacerbations of COPD that require either systemic corticosteroids (intramuscular (IM), intravenous, or oral) and/or antibiotics. Severe COPD exacerbation is defined as acute exacerbation of COPD requiring hospitalization or emergency room / urgent care visit ≥ 24 hours.	Over 52 Weeks
The number of participants experiencing an adverse events (AEs)	The number of participants experiencing an AE (an AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship) will be presented.	Over 52 weeks
Changes in vital sign parameters	Vital signs, including systolic and diastolic BP (mmHg), heart rate (beats per minute), body temperature (°C), and respiratory rate will be listed and summarized.	Over 52 weeks
Changes in electrocardiogram (ECG) parameters	ECG (graphical tracing that records the electrical signals of your heartbeat) parameters will be summarized.	Over 52 weeks
Number of Participants with Clinically Significant Changes in Physical Examination Findings	Physical examination will be performed at each study visit by a qualified investigator. The following body systems will be assessed: ears, nose, throat, skin, cardiovascular, respiratory, musculoskeletal, and neurological.	Over 52 weeks
Number of participants with clinically significant abnormalities	Clinical laboratory assessments including hematology, serum chemistry, and urinalysis will be performed at each study visit.	Over 52 weeks
Changes in Physical Exam Parameters - Body Weight	Body weight measured using a calibrated scale at each study visit	Over 52 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time to first moderate or severe COPD exacerbation	Effect of EXPD-101/FXS7553 compared with placebo on time to first moderate or severe COPD exacerbation.	Over 52 Weeks
Change From Baseline in Quality of Life Questionnaire - St. George's Respiratory Questionnaire (SGRQ)	The SGRQ is a validated, self-administered patient-reported outcome (PRO) that assesses symptoms, functioning, and health-related quality of life for participants with Chronic Obstructive Pulmonary Disease (COPD). It contains 50 items in 2 parts. Part 1 has 8 items for assessing the severity of respiratory symptoms (cough, sputum production, wheeze, breathlessness, and the duration and frequency of attacks of breathlessness or wheeze). Part 2 has 42 items across 2 components (Activity and Impacts) related to daily activities and psychosocial impacts of the participant's respiratory condition. The SGRQ total score is calculated as the sum of scores across symptoms, activity, and effects, with 0 indicating the best possible health status and 100 indicating the worst possible health status. A decrease in 4 units in the total score corresponds to a clinically significant improvement in the quality of life.	Baseline, Week 52
Change From Baseline at Week 52 in Postbronchodilator Forced Expiratory Volume in 1 Second (FEV1) and forced vital capacity (FVC)	FEV1 is used to assess lung function and is the maximum amount of air that can be forced out in one second after first second after taking a forced expiration as measured by a spirometer. Postbronchodilator FEV1 tests included spirometry tests performed after administration of bronchodilator. FVC is used to assess lung function and is the total volume of air that can be forced out after taking a deep breath as measured by a spirometer.	Baseline, Week 52
Change From Baseline at Week 52 in Quality of Life Questionnaire - Evaluating Respiratory Symptoms (E-RS): COPD	The E-RS:COPD™ scale, a part of the EXACT tool, is a derivative instrument used to measure the effect of treatment on the severity of respiratory symptoms in stable COPD. The E-RS is an 11-item participant-reported diary to measure respiratory symptom items contained in the 14-item EXACT. Summation of E-RS: COPD item responses produces a total score ranging from 0 to 40, with higher scores indicating greater severity. In addition to the total score, symptom domain scores can be calculated for breathlessness (5 items; score range: 0-17), cough and sputum (3 items; score range: 0-11) and chest symptoms (3 items; score range: 0-12) by summing the responses of items within a respective domain. As with the total score, higher domain scores indicate greater severity.	Baseline, Week 52
Annualized rate of severe COPD exacerbations	Effect of EXPD-101/FXS7553 compared with placebo on rate of severe COPD exacerbations.	Over 52 Weeks
Plasma Concentration and metabolites of EXPD-101/FXS755		Pre-dose at baseline, and Weeks 2, 4, 12, 28, 52 and 56.
Change from Baseline in sputum neutrophil elastase (NE) activity	Effect of EXPD-101/FXS7553 compared with placebo on sputum neutrophil elastase (NE) activity.	Over 52 Weeks
Annualized rate of COPD exacerbations requiring Emergency Department visit and/or hospitalization	Effect of EXPD-101/FXS7553 compared with placebo on rate of COPD exacerbations requiring Emergency Department visit and/or hospitalization.	Over 52 Weeks

Collaborators and Investigators

• Sponsor: Expedition Therapeutics, Inc
• Investigators: Study Chair: James Duncan Chalmers, MBChB, PhD, Radcliffe Department of Medicine, University of Oxford

Study record dates

Study Major Dates

• Study Start (Estimated): June 30, 2026
• Primary Completion (Estimated): June 30, 2028
• Study Completion (Estimated): July 11, 2028

Study Registration Dates

• First Submitted: May 6, 2026
• First Submitted That Met QC Criteria: June 29, 2026
• First Posted (Actual): July 6, 2026

Study Record Updates

• Last Update Posted (Actual): July 6, 2026
• Last Update Submitted That Met QC Criteria: June 29, 2026
• Last Verified: June 1, 2026

More Information

Terms related to this study

• Keywords: COPD; Chronic Obstructive Pulmonary Disease; Bronchitis; DPP; DPP1; DPP Inhibitor; DPP1 Inhibitor
• Additional Relevant MeSH Terms: Pathologic Processes; Chronic Disease; Disease Attributes; Respiratory Tract Infections; Infections; Respiratory Tract Diseases; Lung Diseases; Bronchial Diseases; Lung Diseases, Obstructive; Pathological Conditions, Signs and Symptoms; Pulmonary Disease, Chronic Obstructive; Bronchitis
• Other Study ID Numbers: EXPD-101-201; 2026-525216-34 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Individual participant data will not be shared externally. Data collected in this study will be used solely for internal analysis and regulatory submission purposes, consistent with participant confidentiality protections and sponsor data governance policies.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No